Insomnia supplement protocol — what works beyond melatonin
Chronic insomnia disorder affects roughly 10% of adults and presents in two main patterns — long sleep onset latency and frequent night-time wakings (often with both). The cornerstone of treatment is CBT-I (cognitive behavioural therapy for insomnia), the AASM and ACP first-line recommendation. Supplements are an adjunct, not a substitute. Within that frame, the better-supported options are glycine, low-dose melatonin (used correctly — 0.3–0.5 mg, not 5–10 mg), magnesium glycinate, valerian (extract-quality dependent), and tart cherry. Most "sleep formulas" overlay sub-therapeutic doses on top of misleading marketing.
The CBT-I-first principle
CBT-I — cognitive behavioural therapy for insomnia — outperforms hypnotic medication for chronic insomnia in head-to-head trials at the durable-outcome timepoint. Components include sleep restriction (counterintuitive but effective), stimulus control, cognitive restructuring around catastrophic sleep thoughts, and sleep hygiene. Digital CBT-I (Sleepio, Somryst) is widely available and meaningfully effective. Supplements at best provide a few percentage points on top of CBT-I; they do not substitute for it.
The supplement layer — what has trial evidence
Glycine
3 g dissolved in water, 30–60 minutes before bed
Three small RCTs (Yamadera 2007, Inagawa 2006, Bannai 2012 review) show shortened sleep onset latency, improved subjective sleep quality, and reduced next-day fatigue. Mechanism: peripheral vasodilation and small core temperature drop facilitating sleep onset. Very low risk, slightly sweet taste, easy to dose. Among non-melatonin options, has the cleanest mechanistic-plus-outcome story.
Melatonin (low dose, 0.3–0.5 mg)
0.3–0.5 mg, 30–60 min before target bedtime
Meta-analyses (Brzezinski 2005, Ferracioli-Oda 2013) show shortened sleep onset latency by ~7 minutes. The 5–10 mg doses on most US shelves are pharmacologically excessive and produce next-day grogginess without better sleep outcomes. Use the smallest effective dose. Most useful for users with age-related decline in endogenous melatonin (older adults) and for circadian phase disorders (delayed sleep-wake phase, shift work, jet lag).
Magnesium glycinate
200–400 mg elemental magnesium, evening dose
Magnesium supports sleep architecture and reduces self-reported anxiety; the glycine component of the chelator contributes independently to sleep quality. Particularly relevant if dietary magnesium intake is low (typical Western diet) or if on PPIs/loop diuretics. Avoid magnesium oxide (poorly absorbed, laxative). Avoid in eGFR <30.
Valerian root extract
400–900 mg standardised extract, 30–60 min before bed
Cochrane and Bent 2006 meta-analyses suggest modest subjective improvement, smaller than effect sizes for prescription hypnotics. Effect develops over 2–4 weeks of nightly use rather than acutely. Extract quality varies widely; standardised preparations have the better evidence. Mild GI effects in some users; rare paradoxical alerting; avoid in liver disease (rare hepatotoxicity reports).
Tart cherry (Montmorency) concentrate
30 mL concentrate twice daily, with one dose 60–90 min before bed; 1–2 week trial
Small RCTs (Pigeon 2010 in older adults, Losso 2018) show modest improvements in sleep time and efficiency. Mechanism: small dietary melatonin content plus anti-inflammatory effects. Concentrate contains significant natural sugar — relevant for diabetic/pre-diabetic users. Best for older adults with low endogenous melatonin or athletes with DOMS-disrupted sleep.
L-Theanine
200–400 mg at bedtime
Most evidence is in daytime calm and focus, less in sleep specifically. Anecdotally useful for the "I can't shut my mind off" sleep-onset pattern. Very low risk. Reasonable trial if glycine and magnesium don't address the specific pattern.
The behavioural and environmental layer
Supplement effect sizes are dwarfed by these behavioural inputs, which should be optimised first:
- Consistent sleep-wake schedule — including weekends; chronotherapy is more powerful than any pill.
- Morning daylight exposure — 10–30 minutes within 1 hour of waking; anchors circadian rhythm.
- Cool, dark, quiet bedroom — 65–68°F (18–20°C); blackout curtains; white noise if needed.
- Caffeine cutoff — at least 8 hours before bed for normal metabolisers; 12 hours for slow metabolisers.
- Alcohol — even modest amounts fragment second-half sleep; "nightcap" sleep is poor sleep.
- Stimulus control — bed only for sleep (and sex); get out of bed if awake >20 min.
- Screen and bright-light reduction — last 60 min before sleep; warm/dim ambient lighting.
What to skip
- High-dose melatonin (3–10 mg) — sedating but no better for sleep outcomes; produces next-day grogginess.
- Diphenhydramine ("PM" formulations like ZzzQuil, Tylenol PM) — anticholinergic burden, hangover effect, and chronic use is associated with cognitive decline in older adults.
- Doxylamine ("Unisom") — same family as diphenhydramine; same concerns.
- CBD products marketed for sleep — modest and inconsistent evidence; product variability; drug-interaction footprint.
- Kava (high-dose extract) — anxiolytic but hepatotoxicity reports preclude safe long-term use.
- "Sleep stack" formulas with proprietary blends — sub-therapeutic doses of individual ingredients hidden under "proprietary blend" labels.
- GABA supplements — GABA doesn't cross the blood-brain barrier; the "sleep" effect is not what marketing implies.
What to track
The Insomnia Severity Index (ISI) is the standard validated 7-item self-report. Sleep diaries (paper or app-based) capture sleep onset latency, wake after sleep onset, total sleep time, and sleep efficiency. Reassess at 4 weeks of any change to the protocol. If the ISI hasn't improved meaningfully in 4 weeks of consistent use, the change is not going to take effect at 8 weeks. Wearable sleep trackers are useful for trend, but the algorithms over-report deep sleep and under-detect awakenings; treat the data as directional, not absolute.